See company ann on 4 April 2007FURTHER POSITIVE TRIAL RESULTS...

See company ann on 4 April 2007

FURTHER POSITIVE TRIAL RESULTS SHOW THAT THE NORWOOD NEEDLE-FREE INJECTION
DEVICE CAN DELIVER TO DIFFERENT DEPTHS
Key points:
· Further Needle-free prototype laboratory trial results
· Important proof of device’s ability to deliver to different depths
Medical technologies group Norwood Abbey Ltd [ASX:NAL] is pleased to advise further progress in the
needle-free injection system project being undertaken at the BioInstrumentation Laboratory at Massachusetts
Institute of Technology (MIT) under the direction of Prof Ian Hunter.
In an announcement on March 13 2007, Norwood reported the successful delivery using the prototype
Needle-free actuator to a specific depth. Norwood now confirms that the recent trials have demonstrated the
ability of the Norwood needle-free device to be programmed to deliver drugs in a controlled manner to
different depths into a human skin substitute.
Programmability and control over the injection parameters also means that a Norwood needle-free injection
device, of a particular power, would be able to be used for the delivery of more than one drug. The
applicability of one device to deliver a wide range of drugs is expected to substantially reduce manufacturing
costs.
A video that has been prepared demonstrating the features described above. MIT has utilised its state-of-theart
video system to record the trial processes at the speed of 30,000 frames per second. Extracts of the
video recording of the tests can be viewed on the company’s website at www.norwoodabbey.com.
The viewer is able to see how, with a simple adjustment to the settings of the prototype device, the target
depth can be varied. Sequential shots from the prototype deliver a compound to increasingly deeper levels.
Norwood, earlier this year, released a video that showed the ability of the technology to be able to
consistently deliver drugs (or vaccines and biologicals) to a constant depth. The video showed and provided
evidence of the efficacy of the technology to deliver through the skin to a prescribed depth, with the majority
of the compound penetrating to the target depth.
The MIT program involved testing delivery using the unique patented drive force that forms part of the
technology licensed by Norwood from MIT under its commercial licensing agreement.
Norwood believes that the ability of the technology to enable any particular sized device to be able to be
used for a number of multiple applications, will both reduce the costs of manufacture (larger production runs
of the same device) as well as be very attractive to pharmaceutical and veterinary groups. Coupled with this
controllability, the silent procedure provides Norwood with an actuator that addresses key aspects of a
functional force for delivery of compounds to animals and humans.
The latest trial results come as Norwood progresses discussions with several global pharmaceutical groups.
Norwood is working to achieve the first commercial arrangements at the earliest possible date.
For further information visit www.norwoodabbey.com and go to
www.norwoodabbey.com/news/NFIControlledDepth to view the video extracts.
For further information please contact:
Norwood Abbey Ltd
Lula Liossi
Corporate Communications